Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

Tran, J Q; Di Cicco, R A; Sheth, S B; Tucci, M; Peng, L; Jorkasky, D K; Hursting, M J; Benincosa, L J

Tran, J Q; Di Cicco, R A; Sheth, S B; Tucci, M; Peng, L; Jorkasky, D K; Hursting, M J; Benincosa, L J.

Affiliation

Tran JQ; SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center, University of Pennsylvania Health System, Philadelphia, USA.

J Clin Pharmacol ; 39(5): 513-9, 1999 May.

Article in En | MEDLINE | ID: mdl-10234600

Subject(s)

Anti-Bacterial Agents/pharmacology; Anti-Bacterial Agents/pharmacokinetics; Antithrombins/pharmacology; Antithrombins/pharmacokinetics; Erythromycin/pharmacology; Erythromycin/pharmacokinetics; Pipecolic Acids/pharmacology; Pipecolic Acids/pharmacokinetics; Adolescent; Adult; Analysis of Variance; Anti-Bacterial Agents/adverse effects; Area Under Curve; Arginine/analogs & derivatives; Cross-Over Studies; Drug Interactions; Erythromycin/adverse effects; Half-Life; Humans; Male; Middle Aged; Sulfonamides

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pipecolic Acids / Antithrombins / Erythromycin / Anti-Bacterial Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Humans / Male / Middle aged Language: En Journal: J Clin Pharmacol Year: 1999 Document type: Article

Search on Google

XML

PubMed Links